Antonio González-Martín, MD
Frontline maintenance therapy with niraparib (Zejula) represents a new standard of care among women with newly diagnosed, platinum-sensitive advanced ovarian cancer, according to data from the phase III PRIMA trial.The data, which were presented at the 2019 ESMO Congress
, demonstrated a 5.6-month extension in progression-free survival (PFS) with niraparib versus placebo in patients with newly diagnosed, advanced disease who achieved a complete or partial response (PR) to platinum-based chemotherapy.
In the overall population, the median PFS was 13.8 months with niraparib versus 8.2 months with placebo (HR, 0.62; 95% CI, 0.50-0.76; P
<.001). Among those who tested positive for homologous recombination deficiency (HRD), the median PFS was 21.9 months versus 10.4 months with niraparib and placebo, respectively (HR, 0.43; 95% CI, 0.50-0.76; P
... to read the full story